Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Sickle-Cell Anemia

Sickle-Cell Anemia

Part of Anemia

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Sickle-Cell Anemia

34 trials tracked for Sickle-Cell Anemia: 7 in phase 3 or 4 and 4 with published results. The most-cited published study has 795 citations.

34Trials tracked
7Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 2 Phase 3 5 Phase 2 15 Phase 1 3 Other / NA 9
  1. Phase 3 Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia Completed · 795 cited
  2. Phase 3 A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia Completed · 549 cited
  3. Phase 3 Novel Use Of Hydroxyurea in an African Region With Malaria Completed · 150 cited
  4. Phase 3 Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease Completed · 55 cited
  5. Phase 4 Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis Completed
  6. Phase 4 Actigraphy Improvement With Voxelotor (ActIVe) Study Completed
Show 28 more trials
  1. Phase 3 Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial Completed
  2. Phase 2 Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies Completed
  3. Phase 2 Hydroxyurea and EPO in Sickle Cell Disease Completed
  4. Phase 2 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Completed
  5. Phase 2 L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia Completed
  6. Phase 2 The Effect of Rivaroxaban in Sickle Cell Disease Completed
  7. Phase 2 Daily Vitamin D for Sickle-cell Respiratory Complications Completed
  8. Phase 2 Management of Severe Acute Malnutrition in SCD, in Northern Nigeria Completed
  9. Phase 2 Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia Completed
  10. Phase 2 Effectiveness of Arginine as a Treatment for Sickle Cell Anemia Completed
  11. Phase 2 A Phase II Trial of Regadenoson in Sickle Cell Anemia Completed
  12. Phase 2 Losartan to Reverse Sickle Nephropathy Completed
  13. Phase 2 Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease Completed
  14. Phase 2 Prasugrel Versus Placebo in Adult Sickle Cell Disease Completed
  15. Phase 2 Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises Completed
  16. Phase 2 Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers Completed
  17. Phase 1 An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults Completed
  18. Phase 1 Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease Completed
  19. Phase 1 A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers Completed
  20. N/A Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence Completed
  21. N/A Evaluation of the AMICUS RBCx System in Sickle Cell Patients Completed
  22. N/A Decision Aid for Therapeutic Options In Sickle Cell Disease Completed
  23. N/A Shared-Decision Making for Hydroxyurea Completed
  24. N/A Microvascular Blood Flow in Sickle Cell Anemia Completed
  25. N/A Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol Completed
  26. N/A Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study) Completed
  27. N/A Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease Completed
  28. N/A Carbon Monoxide Measurement to Screen for Sickle Cell Disease Completed

Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Sickle-Cell Anemia: what the trials found

Hydroxyurea treatment is associated with significant improvements in hemoglobin levels and fetal hemoglobin percentages. Specifically, patients showed a median increase in fetal hemoglobin of 1.70% to 8.00% (p=0.0005) and mean hemoglobin increases ranging from 0.42 to 1.15 g/dL (p=0.033) 12. Additionally, a specific cohort showed a 15% response rate in the percentage of participants with a hemoglobin response 1.

L-glutamine has been shown to significantly reduce the number of sickle cell crises (p=0.0052) and hospitalizations for sickle cell pain (p=0.0045) 5. While another trial observed similar trends in crisis occurrences, hospitalization frequency, and emergency room visits, these specific outcomes did not reach statistical significance 13.

Voxelotor demonstrated a 41.7% success rate for patients achieving a >1 g/dL increase in hemoglobin at week 12, which decreased to 26.1% by week 24 2. Other interventions like Rivipansel did not show statistically significant differences in time to discharge or cumulative IV opioid consumption 7.

Fentanyl Citrate was associated with a significant reduction in pain scores (p=0.048) and a lower incidence of headaches (p=0.05) compared to the control group 3. Transfusion therapy is also established as an intervention for this condition 8.

Recent results — preliminary, needs further review

  • Daily oral vitamin D3 (3,333 IU) was evaluated regarding the ratio of residual lung volume to total lung capacity, though specific significance was not noted in the provided data 9.

For the clinician treating this condition

  • Hydroxyurea is supported by evidence for increasing both hemoglobin and fetal hemoglobin levels 12.
  • L-glutamine may be effective in reducing the frequency of sickle cell crises and associated hospitalizations 5.
  • Voxelotor shows a measurable impact on hemoglobin levels at 12 weeks, though this effect appears to diminish by week 24 2.
  • Fentanyl Citrate is associated with improved pain scores and reduced headache incidence in clinical settings 3.

AI synthesis of 9 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review finds first FDA-approved CRISPR therapy and broader clinical trial exploration
Genetics & Precision Medicine Sys. Review
Systematic review finds first FDA-approved CRISPR therapy and broader clinical trial exploration First CRISPR gene therapy approved for blood disorders, with broader research underway
A systematic review of clinical trials registered at clinicaltrials.gov found the first CRISPR-Cas9 therapy obtained FDA approval in late 20…
The first CRISPR gene therapy is approved for sickle-cell anemia and β-thalassemia, with ongoing trials exploring its use for cancer and inf…
Frontiers Apr 3, 2026
Report examines use of recommended health care measures for sickle cell anemia complications in youth
Hematology
Report examines use of recommended health care measures for sickle cell anemia complications in youth Report examines use of preventive care for children with sickle cell anemia
A report describes the use of recommended health care measures to prevent complications of sickle cell anemia in children and adolescents in…
A new report looked at how children and adolescents with sickle cell anemia in the U.S.
CDC Apr 2, 2026

Research across Anemia

Related studies from across the Anemia family.

Bismuth quadruple and concomitant regimens achieve >85% H. pylori eradication amid rising clarithromycin resistance
Gastroenterology Sys. Review
Bismuth quadruple and concomitant regimens achieve >85% H. pylori eradication amid rising clarithromycin resistance H. pylori treatments failing as resistance grows, review finds
This narrative review synthesizes current H. pylori eradication strategies, noting that clarithromycin resistance exceeds 15%-20% in most re…
Clarithromycin resistance now tops 15-20% in most regions, but bismuth quadruple and other combos still clear the bug over 85% of the time.
Frontiers Jul 29, 2026
Maternal anaemia research surges 9-fold from 2000 to 2024, but gaps persist in low-income regions
Psychiatry Guideline
Maternal anaemia research surges 9-fold from 2000 to 2024, but gaps persist in low-income regions Mapping the Growth and Trends of Research on Maternal Anaemia Over Time
A bibliometric analysis of 1,007 articles on maternal anaemia (2000-2024) shows exponential publication growth (R2=0.9054). Most research or…
A massive review of over 1,000 articles shows how research on anemia in pregnant women has grown rapidly since 2000.
Frontiers Jul 26, 2026
Surgery achieves 70% single-surgery anatomical success in sickle cell retinopathy
Ophthalmology Meta-analysis
Surgery achieves 70% single-surgery anatomical success in sickle cell retinopathy Surgery for Sickle Cell Retinopathy Shows 70% Success Rate
This systematic review and meta-analysis of 7 studies (408 eyes) found that surgical treatment for sickle cell retinopathy yields a pooled s…
A review of 7 studies finds surgery for sickle cell retinopathy has a 70% single-surgery success rate and improves vision.
Frontiers Jul 24, 2026
Endoscopic investigation for iron deficiency anemia reveals 52.0% prevalence of normal upper gastrointestinal findings
Gastroenterology Meta-analysis
Endoscopic investigation for iron deficiency anemia reveals 52.0% prevalence of normal upper gastrointestinal findings Understanding the Common Findings in Endoscopy for Patients with Iron Deficiency
This meta-analysis of 9,807 adults with confirmed iron deficiency anemia (IDA) evaluated the prevalence of gastrointestinal findings during …
Doctors use endoscopy to find the cause of low iron. This study shows what common issues are found during these tests.
Jul 1, 2026
FANCI overexpression linked to poor prognosis in multiple cancers, review finds
Urology Sys. Review
FANCI overexpression linked to poor prognosis in multiple cancers, review finds Protein called FANCI may play role in cancer progression
This narrative review examines the multifaceted roles of FANCI, a Fanconi anemia protein, in DNA repair and cancer. The authors report that …
A protein known as FANCI helps repair DNA but its presence in high amounts can lead to worse outcomes for some cancer patients.
Frontiers Jun 30, 2026
AI-augmented screening improves hereditary hemolytic anemia detection with 92.8% pooled sensitivity
Hematology Meta-analysis
AI-augmented screening improves hereditary hemolytic anemia detection with 92.8% pooled sensitivity AI tools improve accuracy for screening hereditary blood disorders
This meta-analysis of 133,498 individuals screened for hereditary hemolytic anemia (HHA) carriers found that AI-augmented complete blood cou…
New data shows that adding artificial intelligence to blood tests can better identify people carrying genes for conditions like sickle cell …
Jun 29, 2026
Roxadustat increases odds of vascular access thrombosis and all-cause mortality in patients with chronic kidney disease
Drug Pipeline Meta-analysis
Roxadustat increases odds of vascular access thrombosis and all-cause mortality in patients with chronic kidney disease Roxadustat Linked to Higher Risk of Blood Clots in Kidney Patients
This systematic review and meta-analysis of 11,418 adults with chronic kidney disease found that roxadustat is associated with higher odds o…
A review of over 11,000 patients suggests roxadustat may increase the risk of blood clots and death for those with chronic kidney disease.
Frontiers Jun 13, 2026
Vitamin D improves strength and reduces injuries in dancers, while iron lowers anemia prevalence
Nutrition & Obesity Medicine Meta-analysis
Vitamin D improves strength and reduces injuries in dancers, while iron lowers anemia prevalence Dancers take many supplements, but benefits are often unproven and risks remain unclear
This systematic review of dietary supplement and medication use in 654 female and 86 male professional and pre-professional dancers found vi…
Dancers use many supplements and painkillers, yet benefits are limited and potential health risks need more study before we can trust them.
Frontiers Jun 4, 2026
Systematic review reveals high prevalence of sickle cell disease across infants and youth in sub-Saharan Africa
Hematology Meta-analysis
Systematic review reveals high prevalence of sickle cell disease across infants and youth in sub-Saharan Africa Sickle cell disease affects nearly 2 percent of kids under 15 in sub-Saharan Africa
A comprehensive meta-analysis of 40 studies from 22 nations highlights the burden of sickle cell disease in sub-Saharan Africa. Prevalence r…
New analysis shows sickle cell disease is more common than thought in infants and children across sub-Saharan Africa, highlighting a critica…
Jun 1, 2026
Systematic review and meta-analysis finds roxadustat improves hemoglobin in peritoneal dialysis patients
Nephrology Meta-analysis
Systematic review and meta-analysis finds roxadustat improves hemoglobin in peritoneal dialysis patients Roxadustat Boosts Hemoglobin in Peritoneal Dialysis Patients
This systematic review and meta-analysis of 607 patients receiving peritoneal dialysis found that roxadustat significantly increased hemoglo…
A review of 607 patients on peritoneal dialysis finds roxadustat raises hemoglobin and iron levels while lowering hepcidin.
May 27, 2026
Narrative review of CRISPR-Cas9 and Fanzor gene therapies for sickle cell disease
Genetics & Precision Medicine Sys. Review
Narrative review of CRISPR-Cas9 and Fanzor gene therapies for sickle cell disease New CRISPR gene therapies for sickle cell disease face lingering technology limits
This narrative review synthesizes evidence on CRISPR-Cas9-based gene therapies and the Fanzor system for sickle cell disease. The authors no…
A review of CRISPR-Cas9 gene therapies for sickle cell disease notes that limitations in the technology still persist.
Frontiers May 26, 2026
Systematic review and meta-analysis of liposomal iron versus conventional iron in pediatric iron deficiency anemia
Pediatrics Meta-analysis
Systematic review and meta-analysis of liposomal iron versus conventional iron in pediatric iron deficiency anemia Liposomal iron improves blood counts and reduces side effects in children with anemia
This systematic review and meta-analysis evaluated liposomal iron versus conventional oral iron in 454 children with iron deficiency anemia …
A meta-analysis found liposomal iron raised hemoglobin more and caused fewer side effects than conventional iron in children.
May 25, 2026